Abstract
The relationship between serum peginterferon pharmacokinetics and pharmacodynamics and the early virologic response (EVR) to peginterferon and ribavirin therapy was assessed in patients with chronic hepatitis C virus (HCV) genotype 1 infection. A total of 333 patients (160 African Americans [AA] and 173 Caucasian Americans [CA]) who received peginterferon alpha-2a (180 microg/wk) without a dose modification during the initial 4 weeks of therapy were analyzed. Peginterferon and 2,5-oligoadenylate synthetase (2,5-OAS) serum levels were measured on days 0, 1, 2, 3, 7, 14, 28, 56, 84, and 168 of treatment. The EVR (>or=2-log(10) decline in HCV RNA levels by week 12 of therapy) was the primary virologic end point. Peginterferon pharmacokinetics after the first dose were similar in AA and CA, but AA had greater peginterferon concentrations at days 1, 3, 14, and 28 (P < .05). AA had higher absolute serum 2,5-OAS levels on days 0, 1, 2, 3, 7, 14, 28, and 56 (P < .05), but the magnitude of 2,5-OAS induction during treatment were similar. AA patients showed a smaller decline in serum HCV RNA during the first 28 days of treatment (P < .001) and a lower EVR (65% vs 83%). AA and CA with EVR had significantly higher serum peginterferon conce...Continue Reading
References
Oct 6, 1998·Annual Review of Biochemistry·G R StarkR D Schreiber
Aug 29, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P GlueR P Clement
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Feb 26, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xuhuai JiXiao-Song He
Oct 16, 2003·Journal of the National Cancer Institute·Dawn HershmanAlfred I Neugut
May 28, 2004·The New England Journal of Medicine·Andrew J MuirUNKNOWN Atlantic Coast Hepatitis Treatment Group
Jun 9, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lennox J JeffersK Rajender Reddy
Jan 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Heather J RibaudoUNKNOWN Adult AIDS Clinical Trials Group Study
Jun 20, 2006·Journal of Hepatology·Marcelo SilvaMark Laughlin
Jul 28, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiao-Song HeHarry B Greenberg
Feb 3, 2007·Journal of Virology·Milton W TaylorSteven H Belle
Citations
Nov 28, 2012·Antimicrobial Agents and Chemotherapy·Mamta K JainTawanda Gumbo
May 29, 2012·The AAPS Journal·Runyan JinThomas C Dowling
Aug 21, 2014·Archives of Virology·Farah Bokharaei-SalimSeyed Moayed Alavian
Sep 3, 2014·The American Journal of Gastroenterology·Sammy SaabFritz Francois
Oct 16, 2012·Digestive Diseases and Sciences·Mauricio Lisker-Melman, José L Walewski
Aug 4, 2012·Clinical Therapeutics·Barbara J BrennanJoseph F Grippo
Oct 19, 2010·Gastroenterology Clinics of North America·Mazen Noureddin, Marc G Ghany
Aug 27, 2010·Journal of Viral Hepatitis·E S A AraújoA A Barone
Apr 4, 2012·Alimentary Pharmacology & Therapeutics·B J BrennanJ F Grippo
Nov 27, 2010·Journal of Viral Hepatitis·A J MuirJ McCone
Oct 20, 2010·Journal of Viral Hepatitis·K KumthipN Maneekarn
Jul 5, 2012·Journal of Hepatology·Souvik SarkarJay H Hoofnagle
Oct 27, 2011·Journal of Hepatology·Charles D HowellBraxton D Mitchell
Dec 19, 2012·Journal of Hepatology·Charles D HowellThomas C Dowling
Dec 17, 2008·Journal of Hepatology·Andrew W Tai, Raymond T Chung
Oct 24, 2012·The American Journal of Gastroenterology·Runyan JinCharles D Howell
Oct 9, 2019·Expert Opinion on Drug Metabolism & Toxicology·Ming-Lun YehWan-Long Chuang